Login to Your Account

Financings Roundup

Tranzyme Prices IPO for GI Drug Development

By Catherine Shaffer

Tuesday, April 5, 2011
Tranzyme Inc. priced an initial public offering (IPO) to raise $54 million to support its pipeline of drugs for gastrointestinal motility disorders. The offering price of $4 per share is one-third its original target of $11 to $13.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription